Life sciences company focused on neuro-pharmaceutical and novel psilocybin drug development for patients with relentless neurological diseases MYND Life Sciences Inc. (CSE: MYND) (OTCMKTS: MYNDF) announced positive preclinical data in measuring dosing accuracy in psilocybins and psilocybin analogs.
Currently, the accurate measurement of psychedelic doses is not possible however, by identifying the functional molecular pathway that most psychedelic compound like psilocybin stimulate MYND Life Sciences has been able to make remarkable progress.
The company announced significant progress in creating a molecular test for calibrating and measuring cellular responses to microdosing with psilocybin. This study was conducted under the supervision of Professor Wilfred Jefferies in the Michael Smith Laboratories at the University of British Columbia via a collaborative agreement with MYND Life Sciences.
The new testing method will allow medical practitioners, researchers and psychedelic companies to monitor and accurately dose psilocybins and psilocybin-containing extracts and compounds.
“This appears to be a significant advance and we hope it will greatly aid in the adoption of psilocybins as mainstream therapies for Major Depressive Disorder and other diseases where the absence of standardizing methodologies have hampered the emergence of new treatments,” said MYND’s chief scientific officer, Wilfred Jefferies.
The company is considering this breakthrough to become the standard in the industry, the results are unique in the industry and methods for quantitating levels of psilocybin and psilocin derivatives that mediate the effects of microdosing.
“Being able to understand and monitor psychedelics at the molecular level is a critical step in differentiating various drugs as they are proposed to treat certain disease states. In the absence of standardizing methodologies such as the one we have now developed, it was difficult to envision how the true potential of psychedelics could have ever been achieved,” said the company’s CEO, Dr. Lyle Oberg.
